News publication
Everything we hold that labonline.com.au published.
Every article we hold from labonline.com.au.
Vaxxas completed a $25 million Series B led by OneVentures, lifting total capital to $40 million, to advance its needle-free Nanopatch vaccine delivery technology toward first clinical studies.
Under SmartCompany ·leads this story in the feed
Biotech startup Vaxxas has raised $15 million in venture capital, led by OneVentures with Brandon Capital, MRCF and HealthCare Ventures, to commercialise the Nanopatch needle-free vaccine delivery technology developed at Queensland university institute AIBN.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·SmartCompany·labonline.com.au
Deals recorded from labonline.com.au's coverage. A round is listed once, however many of their articles mention it.
Companies named in labonline.com.au's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Vaxxas | 2 | |
| Merck | 1 | |
| University of Queensland | 1 |
Investors named in labonline.com.au's articles, most-covered first.